Clinical Evaluation of Blood-Based Assays for Rapid Detection of Aβ Pathology in Alzheimer's Disease

Inclusion Criteria

• •Patient Group (including MCI, AD, and Non-AD Dementia):
• •1. Clear complaints of cognitive impairment, with MCI and AD diagnoses meeting the NIA-AA 2011 diagnostic criteria. Non-AD dementia is defined as patients with cognitive decline diagnosed with dementia due to other reasons (including but not limited to FTD, DLB, VD, PDD, etc.).
• •2. Able to provide informed consent or have a legal guardian who can sign the consent form.
• •3. Completed a full set of cognitive assessments, including MMSE and CDR.
• •4. Able to provide a history of chronic diseases, including cardiovascular diseases, diabetes, etc., and medication history.
• •5. Have undergone amyloid protein PET scans that meet the quality requirements of this study (tracers PiB, AV1, or AV45), and can provide original imaging data for quantitative analysis without conflict.
• •6. Can provide frozen plasma from a biobank collected after January 1, 2024, with a time interval of ≤3 months from the amyloid protein PET scan. If no frozen plasma is available, willing to provide an additional 5ml of whole blood for biomarker testing in this project. The process of blood collection, plasma separation, storage, and transportation meets the quality requirements of this study (see blood testing SOP).
• •7. Have 3D-T1 structural MRI images taken within 3 months before and after the amyloid protein PET scan and can provide original imaging data without conflict.
• •Normal Control Group:
• •1. Subjects with a CDR score of 0 and who have undergone amyloid protein PET scans that are negative.
• •2. Able to provide informed consent.
• •3. Completed a full set of cognitive assessments, including MMSE and CDR.
• •4. Able to provide a history of chronic diseases, including cardiovascular diseases, diabetes, etc., and medication history.
• •5. Have undergone amyloid protein PET scans that meet the quality requirements of this study (tracers PiB, AV1, or AV45), and can provide original imaging data for quantitative analysis without conflict.
• •6. Can provide frozen plasma from a biobank collected after January 1, 2024, with a time interval of ≤3 months from the amyloid protein PET scan. If no frozen plasma is available, willing to provide an additional 5ml of whole blood for biomarker testing in this project. The process of blood collection, plasma separation, storage, and transportation meets the quality requirements of this study (see blood testing SOP).
• •7. Have 3D-T1 structural MRI images taken within 3 months before and after the amyloid protein PET scan and can provide original imaging data without conflict.